Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Breast Cancer
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Other
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Patients enrolled in the study will receive the following interventions: Biospecimen sample collection: before and during treatment, and at progression Tumor biopsy before treatment and at progression The aim of this study is to describe molecular changes associated with resistance to Palbociclib at...
Patients enrolled in the study will receive the following interventions: Biospecimen sample collection: before and during treatment, and at progression Tumor biopsy before treatment and at progression The aim of this study is to describe molecular changes associated with resistance to Palbociclib at the individual level and describe longitudinal changes in the profile of tumor, VOCs and exosomes according to treatment response. Other objectives of the study include: Proportion of single or shared molecular alterations / signatures between patients at progression time Associations between tumor signatures, VOCs and exosomes Compare molecular changes identified by proteomics with those observed by genomics / transcriptomics Compare the evolution of VOCs and exosomes over time with evolution of liquid biopsy markers.
Tracking Information
- NCT #
- NCT04653740
- Collaborators
- Laboratoire PRISM - Michel SALZET
- Investigators
- Not Provided
Get Well Soon